Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product ...
Zoetis targets new therapeutic white spaces—oncology, cardiology, and renal disease—minimizing risk and offering substantial ...
AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and ...
TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...
2026 is shaping up to be a pivotal year for rare disease drugmakers, with key approvals, filings and readouts lined up for ...
Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine ...
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory ...
Infosys (NSE: INFY) (BSE: INFY) , a global leader in next-generation digital services and consulting, and ATP, global ...
Therapies market, valued at USD 16.7 million in 2024, is expected to register robust revenue CAGR of 44.6%.Request free copy of this report: 13, 2026- The growing incidence of autoimmune disorders ...
Understanding human gene function in living organisms has long been hampered by fundamental differences between species.
Researchers at Colorado State University have determined how to use artificial intelligence to modify antibodies so they act ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback